Brian K

Two storms charging across the Pacific are on Bloomberg Green’s radar today.

Storms in the Pacific are on Bloomberg Green’s radar today.

There’s more than two months left in the year, but the US has already faced a record number of disasters costing $1 billion or more in 2023, with 24 such events. That tally is likely grow even bigger as officials assess the costs of Hurricane Hillary, hail storms that hit Texas last month and flooding in New York.

(Bloomberg) -- There’s more than two months left in the year, but the US has already faced a record number of disasters costing $1 billion or more in 2023, with 24 such events. That tally is likely grow even bigger as officials assess the costs of Hurricane Hillary, hail storms that hit Texas last month and flooding in New York.Most Read from BloombergIsrael Latest: Top US General Warns Iran to Stay Out of ConflictHamas Got Around Israel’s Surveillance Prowess by Going DarkSchumer Confronts Xi o

Quedan más de dos meses para que termine el año, pero Estados Unidos ya se ha enfrentado a un número récord de desastres con un costo de US$1.000 millones o más, con 24 eventos de este tipo en 2023. Es probable que esa cifra crezca aún más a medida que los funcionarios evalúen los costos de del huracán Hillary, las tormentas de granizo que azotaron Texas el mes pasado y las inundaciones en Nueva York.

A super typhoon is on Bloomberg Green’s radar today.

An abstract is unavailable.

Extreme heat is usually associated with drought and wildfires. But across five continents this year, it’s also unleashed a different kind of disaster: deadly flooding.

Strange things happening in the Atlantic are on Bloomberg Green’s radar today.

Tamoxifen (TAM) is a drug commonly used in patients with breast cancer. The anticancer effect of TAM occurs via its ability to antagonize estrogen-dependent growth of mammary epithelial cells. Previously, we demonstrated that TAM prevented the chemotherapy-induced loss of ovarian follicular reserves in both cancer-free rats and rats with cancer. Such follicular loss is a main cause of infertility in young women treated for cancer. The current study was undertaken to discover the molecules and intracellular pathways involved in the action of TAM in the ovaries of rats with mammary tumors. To meet this goal we used transcriptomic (RNA-Seq) and proteomic (2D-DIGE/MS) approaches. TAM inhibited the expression of genes and lncRNAs involved in ovarian steroidogenesis. Moreover, TAM altered the expression of genes related to primordial follicle activation or arrest. In addition, proteomic screening indicated the importance of basic metabolic processes in the ovarian actions of TAM. Although simple extrapolation of these data to humans is not possible, the results of this study emphasize the need to explore the ability of TAM to affect ovarian function in women undergoing cancer treatment.